Please assess the completion status of the following clinical trial:

Trial Title: Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA: (Screening)~A subject will be eligible for participation in the screening portion of this protocol if all of the following criteria apply:~1. Between 18 and 65 years of age~2. Residence in or travel to a Loa-endemic region for greater than 1 month~EXCLUSION CRITERIA: (Screening)~A subject will not be eligible for participation in the screening portion of this study if any of the following conditions apply:~1. Known to be pregnant~2. Known to be HIV-positive~INCLUSION CRITERIA: (Interventional Study)~A subject will be eligible for participation in the interventional portion of the study only if all of the following criteria apply:~1. The subject has documented loiasis with 0-5000 microfilariae/mL blood.~2. The subject agrees to storage of samples for study~3. A female subject is eligible for this study if she is any of the following:~   * Not pregnant or breast-feeding.~  * Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are post-menopausal, as defined by no menses in greater than or equal to 1 year)~  * Of childbearing potential but agrees to practice effective contraception\* or abstinence for 3 months after administration of the investigational study drug (reslizumab or placebo)~     * NOTE: Acceptable methods of contraception may include one or more of the following: 1) male partner who is sterile prior to the female subject s entry into the study and is the sole sexual partner for the female subject; 2) implants of levonorgestrel; 3) injectable progestogen, an intrauterine device with a documented failure rate of less than 1percent; 4) oral contraceptives; and 5) double barrier methods including diaphragm or condom with a spermicide.~EXCLUSION CRITERIA: (Interventional Study)~A subject will not be eligible to participate in the interventional portion of the study if any of the following conditions are fulfilled at the time of enrollment:~1. The subject tests positive for HIV infection or has any other known immunodeficiency.~2. The subject has a concomitant active infection with Onchocerca volvulus.~3. The subject has used any other investigational agent within the past 30 days.~4. The subject has used immunosuppressive agents (as listed in section 8.1) within the past 30 days.~5. The subject has a history of allergic reaction to any antibody therapy or to DEC.~6. The subject has chronic kidney or liver disease.~7. The subject has any condition that, in the Investigator s opinion, places the subject at undue risk by participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Reslizumab + DEC (Type: ACTIVE_COMPARATOR): Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
- Placebo + DEC (Type: PLACEBO_COMPARATOR): Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).